EE05191B1 - Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine - Google Patents

Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine

Info

Publication number
EE05191B1
EE05191B1 EEP200200245A EEP200200245A EE05191B1 EE 05191 B1 EE05191 B1 EE 05191B1 EE P200200245 A EEP200200245 A EE P200200245A EE P200200245 A EEP200200245 A EE P200200245A EE 05191 B1 EE05191 B1 EE 05191B1
Authority
EE
Estonia
Prior art keywords
tolterodine
hours
active ingredient
relates
pharmaceutical formulation
Prior art date
Application number
EEP200200245A
Other languages
English (en)
Estonian (et)
Inventor
Nilvebrant Lisbeth
Hall�n Bengt
Olsson Birgitta
Str�mbom Jan
Gren Torkel
Ringberg Anders
Wikberg Martin
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56290073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05191(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/002052 external-priority patent/WO2000027364A1/en
Priority claimed from SE0000782A external-priority patent/SE0000782D0/xx
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of EE200200245A publication Critical patent/EE200200245A/xx
Publication of EE05191B1 publication Critical patent/EE05191B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EEP200200245A 1999-11-11 2000-10-24 Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine EE05191B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
SE0000782A SE0000782D0 (sv) 1999-11-11 2000-03-09 Pharmaceutical formulation and its use
PCT/SE2000/002061 WO2001034139A1 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use

Publications (2)

Publication Number Publication Date
EE200200245A EE200200245A (et) 2003-06-16
EE05191B1 true EE05191B1 (et) 2009-08-17

Family

ID=56290073

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200245A EE05191B1 (et) 1999-11-11 2000-10-24 Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine

Country Status (24)

Country Link
US (1) US6630162B1 (cs)
EP (1) EP1227806B1 (cs)
JP (1) JP2003513918A (cs)
KR (2) KR20070091374A (cs)
CN (1) CN100353935C (cs)
AT (1) ATE300941T1 (cs)
AU (1) AU784104B2 (cs)
BR (1) BR0015346A (cs)
CA (1) CA2387973C (cs)
CZ (1) CZ304671B6 (cs)
DE (1) DE60021749T2 (cs)
DK (1) DK1227806T3 (cs)
EE (1) EE05191B1 (cs)
ES (1) ES2245320T3 (cs)
HK (1) HK1054196B (cs)
HU (1) HUP0203028A3 (cs)
MX (1) MXPA02004574A (cs)
NO (1) NO20022264L (cs)
NZ (1) NZ518309A (cs)
PL (1) PL356166A1 (cs)
PT (1) PT1227806E (cs)
SI (1) SI1227806T1 (cs)
SK (1) SK6412002A3 (cs)
WO (1) WO2001034139A1 (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE60021749T2 (de) * 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
DE10224556A1 (de) * 2002-05-31 2004-01-08 Grünenthal GmbH 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
KR20070091049A (ko) * 2002-12-13 2007-09-06 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
MXPA05007767A (es) † 2003-01-22 2006-01-31 Pfizer Health Ab Dosis reducida de tolterodina y otros agentes antimuscarinicos para tratar trastornos urinarios.
SE0300830D0 (sv) * 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004105735A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
CN100382794C (zh) * 2004-08-30 2008-04-23 鲁南制药集团股份有限公司 酒石酸托特罗定的分散片剂型
CN1795845B (zh) * 2004-12-23 2010-10-13 李又欣 作为毒蕈碱受体拮抗剂的3，3-二苯基丙胺衍生物注射用缓释微球制剂
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
US20070248670A1 (en) * 2006-04-21 2007-10-25 Van Den Heuvel Dennie J M Tolterodine beads
CZ298448B6 (cs) * 2006-08-09 2007-10-03 Zentiva, A. S. Farmaceutická kompozice s obsahem tolterodinu
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2009080061A1 (en) * 2007-12-20 2009-07-02 Pharmathen S.A. Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
JP5878022B2 (ja) * 2009-02-23 2016-03-08 アデア ファーマスーティカルズ，インコーポレイテッド 抗コリン薬を具える放出制御組成物
WO2011013082A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011077239A2 (en) 2009-12-23 2011-06-30 Lupin Limited Slow release pharmaceutical compositions of iloperidone
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
US8392016B2 (en) 2010-06-25 2013-03-05 LNT PM Inc. Adaptive method for manufacturing of complicated shape parts by hot isostatic pressing of powder materials with using irreversibly deformable capsules and inserts
US8940763B2 (en) 2011-05-10 2015-01-27 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
MX369315B (es) 2013-10-07 2019-11-05 Impax Laboratories Inc Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos.
EP3182970A4 (en) * 2014-08-22 2018-03-21 Medipath Inc. Compositions and methods for cannabinoid coatings for use in drug delivery
BR112018014661A2 (pt) 2016-01-20 2018-12-11 Theravida Inc composição e composição para uso
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
AU666735B2 (en) 1992-05-13 1996-02-22 Alza Corporation Transdermal administration of oxybutynin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
JPH0710745A (ja) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd 放出開始時間制御型腸デリバリー経口製剤
JP3453186B2 (ja) * 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
WO1996012477A1 (en) 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU4421697A (en) 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
JPH11193271A (ja) * 1997-10-31 1999-07-21 Ss Pharmaceut Co Ltd アリール酢酸アミド誘導体又はその塩及びこれを含有する医薬
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN1239152C (zh) * 1998-08-27 2006-02-01 法玛西雅和厄普约翰公司 控释给药托耳替罗地的治疗制剂
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
DE60021749T2 (de) * 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung

Also Published As

Publication number Publication date
PL356166A1 (en) 2004-06-14
SK6412002A3 (en) 2002-09-10
CN100353935C (zh) 2007-12-12
EE200200245A (et) 2003-06-16
NZ518309A (en) 2003-05-30
KR100838930B1 (ko) 2008-06-16
JP2003513918A (ja) 2003-04-15
ES2245320T3 (es) 2006-01-01
CA2387973C (en) 2009-12-22
AU1319201A (en) 2001-06-06
DE60021749D1 (de) 2005-09-08
BR0015346A (pt) 2002-06-25
DE60021749T2 (de) 2006-04-20
NO20022264D0 (no) 2002-05-13
EP1227806A1 (en) 2002-08-07
HK1054196A1 (zh) 2003-11-21
CN1420767A (zh) 2003-05-28
CZ304671B6 (cs) 2014-08-27
MXPA02004574A (es) 2004-09-10
ATE300941T1 (de) 2005-08-15
PT1227806E (pt) 2005-10-31
US6630162B1 (en) 2003-10-07
HUP0203028A3 (en) 2005-07-28
AU784104B2 (en) 2006-02-02
KR20070091374A (ko) 2007-09-10
SI1227806T1 (sl) 2005-12-31
DK1227806T3 (da) 2005-10-31
HUP0203028A2 (hu) 2003-02-28
EP1227806B1 (en) 2005-08-03
WO2001034139A1 (en) 2001-05-17
CA2387973A1 (en) 2001-05-17
KR20020062302A (ko) 2002-07-25
HK1054196B (zh) 2008-08-01
CZ20021617A3 (cs) 2002-11-13
NO20022264L (no) 2002-05-13

Similar Documents

Publication Publication Date Title
EE05191B1 (et) Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
MXPA02005536A (es) Acidos aminopropilfosfinicos novedosos.
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
NZ504618A (en) Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
BG102857A (en) Antimycotic substance-containing and acetate buffer-containing compositions
RU2002117649A (ru) Фармацевтические композиции, содержащие золмитриптан
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
SE0102055D0 (sv) New Compounds
IL148874A0 (en) Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them
SE0102440D0 (sv) New compound
EP0779889A4 (en) PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EG19302A (en) Compound with gastric acid inhibitory effect and process for its preparation
NO179094C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for påföring på slimhinnen
IE780217L (en) 1,3,5-triazine-2,6-dione derivatives
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
SE9202218D0 (sv) Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation
SE0000782D0 (sv) Pharmaceutical formulation and its use
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
ES2145740T3 (es) Composiciones de factor de crecimiento, preparacion y uso.
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
IT1306186B1 (it) Sali non igroscopici di principi attivi ad attivita' terapeutica e/onutrizionale e composizioni atte alla somministrazione orale

Legal Events

Date Code Title Description
HD1A Correction of address
KB4A Valid patent at the end of a year

Effective date: 20101231